|
Cancer type | Role of PPAR | TZD | Experimental model | Result | Reference |
|
| |
PIO | Xenograft (HT-29) in mice with APC mutation, sc | Increased tumor growth | [41] |
Colon | / | | Azoxymethane-induced murine tumors | Reduced tumor growth | [39] |
TRO | HT-29 xenografts, sc | Reduced tumor growth and metastasis | [40] |
| | | Metastatic colon cancer, 25 patients | All progressive disease | [43] |
|
Lung | / | ROSI | Chemically-induced mouse model | Decrease in adenoma formation | [46] |
|
| | ROSI | LMM3 injection into mice, sc | Decreased tumor growth | [48] |
Breast | | | Chemically induced rat model | Decreased tumor growth and incidence | [49] |
TRO | Advanced chemotherapy breast refractory cancer, 22 patients | No CR or PR, 3 SD | [50] |
| | ROSI | Early stage breast cancer, 38 patients | No decrease in proliferation | [51] |
|
| | PIO | PC3 xenografts, sc. | Decrease of bone-invasive potential | [53] |
Prostate | |
TRO | Advanced prostate carcinoma, 41 patients | Stabilization of PSA levels | [54] |
| |
ROSI | Recurrent prostate carcinoma, 1 patient | Delayed increase of PSA levels | [55] |
|
Glioma | | PIO | LN229 orthotopic xenografts | Reduced tumor volume, invasion | [58] |
| Chemorefractory glioma, 14 patients | Disease stabilization (29%) | [59] |
|
Melanoma | | CIGLI | A375 xenografts, sc. | Growth inhibition, pro-apoptotic effects | [62] |
|
| |
PIO | Transgenic mouse model (PPAR fusion protein/PTEN deletion) | Decreased tumor growth and metastasis | [106] |
Thyroid | |
ROSI | Transgenic mouse model (Thyroid hormone receptor- negative) | Delayed progression | [107] |
| | | Metastatic thyroid cancer, 1 patient | Decrease in metastasis size | [109] |
|